ClinicalTrials.gg

Program

secukinumab

Also written as “Secukinumab”, “AIN457” and “Secukinumab 300 mg”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylitis, Ankylosing · Arthritis, Rheumatoid · Hidradenitis Suppurativa, led by 3 companies.

Furthest: phase 4, since Jul 12, 2015128 company-led studies, 4 open or runningNext primary completion: Feb 8, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis1254 open or runningphase 4since Jul 12, 2015Dec 21, 2007Feb 8, 2028phase 4 · NCT05622708
Taizhou Mabtech Pharmaceutical20 open or runningphase 1since Jan 29, 2023Jan 29, 2023none ahead
Johnson & Johnson10 open or runningphase 1since Oct 13, 2020Oct 13, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Feb 25, 2015.

  1. Jun 15, 2021Phase 3 study in Giant Cell ArteritisNovartis · NCT04930094 · 354 enrolled · United States, Argentina, Australia and more
  2. Jan 12, 20222 phase 3 studiesNovartis · NCT05206591, NCT05232864
  3. Feb 22, 2022Phase 3 study in Giant Cell ArteritisNovartis · NCT05380453 · 151 enrolled · Germany
  4. Oct 4, 2022Phase 3 study in TendinopathyNovartis · NCT05569174 · 62 enrolled · Germany
  5. Nov 9, 2022Phase 4 study in Non-Radiographic Axial SpondyloarthritisNovartis · NCT05622708 · 240 enrolled · Belgium, Brazil, Colombia and more
  6. Jan 27, 2023Phase 3 study in Rotator Cuff TendinopathyNovartis · NCT05722522 · 33 enrolled · United States, Argentina, Bulgaria and more
  7. Jan 29, 2023Taizhou Mabtech Pharmaceutical's first study: phase 1 study in PsoriasisNew to Taizhou Mabtech PharmaceuticalTaizhou Mabtech Pharmaceutical · NCT05734482 · 130 enrolled · China
  8. Feb 1, 2023Phase 3 study in Rotator Cuff TendinopathyNovartis · NCT05758415 · 60 enrolled · United States, China, Italy and more
  9. Mar 6, 2023Phase 3 study in Polymyalgia RheumaticaNovartis · NCT05767034 · 381 enrolled · United States, Argentina, Australia and more
  10. Nov 8, 2023Phase 1 study in Giant Cell ArteritisNovartis · NCT06130540 · 65 enrolled · United States, Czechia, Italy and more
  11. Mar 20, 2024Phase 3 study in Polymyalgia RheumaticaNovartis · NCT06331312 · 162 enrolled · United States, Argentina, Australia and more
  12. Dec 20, 2024Phase 1 study in Arthritis, JuvenileNovartis · NCT06751238 · 20 planned · United States
  13. Nov 19, 2025Phase 1 study in PsoriasisTaizhou Mabtech Pharmaceutical · NCT07254325 · 114 enrolled · China
  14. Mar 18, 2026Phase 4 study in Hidradenitis SuppurativaNovartis · NCT07489573 · 36 planned · China

Ahead

  1. Feb 8, 2028Primary completion: phase 4 study in Non-Radiographic Axial SpondyloarthritisNovartis · NCT05622708
  2. May 8, 2028Primary completion: phase 3 study in Polymyalgia RheumaticaNovartis · NCT06331312
  3. Sep 25, 2029Primary completion: phase 4 study in Hidradenitis SuppurativaNovartis · NCT07489573
  4. Oct 31, 2029Primary completion: phase 1 study in Arthritis, JuvenileNovartis · NCT06751238

TargetBeta

IL17A →read by rule
“A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), ”NCIt, by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
ixekizumabruleEli Lillyphase 438
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

The newest 60 of 128 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07489573Hidradenitis Suppurativa · China4RecruitingNovartisSep 25, 202936
NCT07254325Psoriasis · China1CompletedTaizhou Mabtech PharmaceuticalJun 12, 2026114
NCT06751238Arthritis, Juvenile · United States1RecruitingNovartisOct 31, 202920
NCT06331312Polymyalgia Rheumatica · United States, Argentina, Australia and more3Active, not recruitingNovartisMay 8, 2028162
NCT06130540Giant Cell Arteritis · United States, Czechia, Italy and more1CompletedNovartisMar 12, 202565
NCT05767034Polymyalgia Rheumatica · United States, Argentina, Australia and more3CompletedNovartisSep 10, 2025381
NCT05758415Rotator Cuff Tendinopathy · United States, China, Italy and more3TerminatedNovartisOct 17, 202460
NCT05734482Psoriasis · China1CompletedTaizhou Mabtech PharmaceuticalJul 3, 2023130
NCT05722522Rotator Cuff Tendinopathy · United States, Argentina, Bulgaria and more3TerminatedNovartisOct 17, 202433
NCT05622708Non-Radiographic Axial Spondyloarthritis · Belgium, Brazil, Colombia and more4Active, not recruitingNovartisFeb 8, 2028240
NCT05569174Tendinopathy · Germany3CompletedNovartisDec 18, 202462
NCT05380453Giant Cell Arteritis · Germany3CompletedNovartisFeb 24, 2026151
NCT05232864Lupus Nephritis · Australia, Brazil, Colombia and more3TerminatedNovartisAug 23, 202331
NCT05206591Active Peripheral Spondyloarthritis (pSpA)3WithdrawnNovartisMar 20, 20280
NCT04930094Giant Cell Arteritis · United States, Argentina, Australia and more3CompletedNovartisApr 11, 2025354
NCT04732117Non-Radiographic Axial Spondyloarthritis · China3CompletedNovartisApr 3, 2024137
NCT04711902Arthritis, Psoriatic · China3CompletedNovartisJun 2, 202241
NCT04737330Graves Ophthalmopathy · Germany3TerminatedNovartisMay 16, 202328
NCT04632927Arthritis, Psoriatic · Germany3CompletedNovartisOct 22, 2024119
NCT04589026Healthy · Belgium1CompletedJohnson & JohnsonMay 6, 202112
NCT04488185Psoriasis4WithdrawnNovartisMar 24, 20210
NCT04237116Non-alcoholic Fatty Liver Disease · Germany, Spain3TerminatedNovartisJun 29, 202110
NCT04300296Lichen Planus · United States, France, Germany2CompletedNovartisNov 16, 2021111
NCT04181762Lupus Nephritis · United States, Argentina, Australia and more3TerminatedNovartisSep 13, 2023275
NCT04179175Hidradenitis Suppurativa · United States, Argentina, Australia and more3CompletedNovartisMay 26, 2023702
NCT04209205Arthritis, Psoriatic · United States, Brazil, Bulgaria and more3CompletedNovartisMay 17, 2022381
NCT04156620Spondylitis, Ankylosing · United States, Belgium, Brazil and more3CompletedNovartisFeb 17, 2022527
NCT03765788Giant Cell Arteritis · Germany2CompletedNovartisJun 8, 202152
NCT03769168Arthritis, Juvenile · United States, Belgium, Germany and more3CompletedNovartisNov 7, 202455
NCT03713632Hidradenitis Suppurativa · United States, Argentina, Belgium and more3CompletedNovartisSep 23, 2021545
NCT03713619Hidradenitis Suppurativa · United States, Argentina, Australia and more3CompletedNovartisOct 1, 2021544
NCT03668613Skin Diseases · United States, Belgium, Czechia and more3CompletedNovartisSep 19, 201984
NCT03589885Plaque Psoriasis · United States, Canada, Germany and more3CompletedNovartisNov 19, 2019122
NCT03504852Psoriasis · United States, Canada, Czechia and more3CompletedNovartisSep 13, 2019331
NCT03344640Tendinopathy · United States, Czechia, Germany and more2CompletedNovartisAug 2, 201996
NCT03350815Spondylitis, Ankylosing · United States4CompletedNovartisMar 11, 2021322
NCT03259074Spondylitis, Ankylosing · United States, Argentina, Australia and more3CompletedNovartisNov 12, 2021859
NCT03136861Spondylarthritis · Belgium, Bulgaria, Croatia and more3CompletedNovartisFeb 15, 2019383
NCT03066609Skin Diseases · China, Hungary, Malaysia and more3CompletedNovartisDec 21, 2017543
NCT03055494Psoriasis · United States4CompletedNovartisApr 25, 2018102
NCT03031782Arthritis, Juvenile · United States, Belgium, Germany and more3CompletedNovartisOct 7, 202086
NCT03020199Psoriasis · Argentina, Bulgaria, Canada and more4CompletedNovartisNov 30, 2021196
NCT02798211Arthritis, Psoriatic · United States, Puerto Rico4CompletedNovartisDec 5, 2018258
NCT02896127Spondylitis, Ankylosing · China, Czechia, Korea, Republic of and more3CompletedNovartisMay 14, 2018458
NCT02763046Spondylitis, Ankylosing · Germany4CompletedNovartisSep 24, 2019211
NCT02750592Spondylitis, Ankylosing · Japan3CompletedNovartisJul 5, 201730
NCT02745080Arthritis, Psoriatic · United States, Australia, Bulgaria and more3CompletedNovartisDec 30, 2019853
NCT02771210Arthritis, Psoriatic · Bulgaria, Czechia, Germany and more3CompletedNovartisDec 11, 2019204
NCT02721966Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more3CompletedNovartisJun 26, 2019503
NCT02748863Psoriasis · United States, Belgium, Canada and more3CompletedNovartisAug 8, 2017214
NCT02690701Psoriasis · United States4CompletedNovartisApr 26, 201791
NCT02752776Plaque, Amyloid · Belgium, Bulgaria, Czechia and more4CompletedNovartisMar 28, 20181,660
NCT02662985Arthritis, Psoriatic · United States, Argentina, Austria and more3CompletedNovartisNov 10, 2020166
NCT02826603Plaque Psoriasis · United States, Canada, Czechia and more3CompletedNovartisJul 9, 20181,114
NCT02607774Moderate to Severe Plaque Psoriasis · United States1CompletedNovartisDec 20, 201625
NCT02696031Axial Spondyloarthritis · United States, Australia, Austria and more3CompletedNovartisJul 1, 2019555
NCT02559622Psoriasis · Germany3CompletedNovartisApr 2016151
NCT02547714Plaque Psoriasis · Japan4CompletedNovartisMay 2, 201634
NCT02474082Psoriasis · Germany3CompletedNovartisJun 2016202
NCT02595970Psoriasis · France3CompletedNovartisFeb 9, 2017120

How it is read

Names in the registry

  • “Secukinumab”, 47 entries
  • “AIN457”, 38 entries
  • “secukinumab”, 7 entries
  • “Secukinumab 300 mg”, 6 entries
  • “Secukinumab (AIN457)”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.